Preclinical experiments are ongoing in our laboratory to validate the efficacy and therapeutic effect of Dapagliflozin on CDK1/PBK/CHEK1 and evaluate the viability of a combination therapy with standard treatments to improve the current chemo-radiotherapy resistance and toxicity status in GBM [49,59,67,68,69,70,71,72]. The gene discussed is CHEK1; the disease is glioblastoma.